These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25935542)

  • 1. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
    Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
    Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
    Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
    Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
    Shibuya H; Hijioka S; Sakamoto Y; Ito T; Ueda K; Komoto I; Kobayashi N; Kudo A; Yasuda H; Miyake H; Arita J; Kiritani S; Ikeda M; Imaoka H; Ueno M; Kobayashi S; Furuta M; Nagashio Y; Murohisa G; Aoki T; Matsumoto S; Motoya M; Azemoto N; Itakura J; Horiguchi S; Yogi T; Kawagoe T; Miyaoka Y; Imamura F; Senju M; Arioka H; Hara K; Imamura M; Okusaka T
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):661-668. PubMed ID: 30054710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
    Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
    Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
    Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
    Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors.
    Schrader J; Henes FO; Blaeker M; Zimmermann-Fraedrich K; Pace A; Perez D; Izbicki JR; Lohse AW; Benten D
    Endocrine; 2019 Aug; 65(2):460-467. PubMed ID: 31037707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
    Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
    Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
    Turner NC; Strauss SJ; Sarker D; Gillmore R; Kirkwood A; Hackshaw A; Papadopoulou A; Bell J; Kayani I; Toumpanakis C; Grillo F; Mayer A; Hochhauser D; Begent RH; Caplin ME; Meyer T
    Br J Cancer; 2010 Mar; 102(7):1106-12. PubMed ID: 20234360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin.
    Gonzalez MA; Biswas S; Clifton L; Corrie PG
    Br J Cancer; 2003 Aug; 89(3):455-6. PubMed ID: 12888810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
    Sun W; Lipsitz S; Catalano P; Mailliard JA; Haller DG;
    J Clin Oncol; 2005 Aug; 23(22):4897-904. PubMed ID: 16051944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
    Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
    Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
    Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
    Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
    Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.
    Müller C; Kreissl MC; Klose S; Krause A; Keitel V; Venerito M
    Medicine (Baltimore); 2022 Jan; 101(4):e28610. PubMed ID: 35089197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
    Kouvaraki MA; Ajani JA; Hoff P; Wolff R; Evans DB; Lozano R; Yao JC
    J Clin Oncol; 2004 Dec; 22(23):4762-71. PubMed ID: 15570077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
    Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
    Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
    Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
    Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
    Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
    Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
    Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.